The trajectory of Gal-3 levels during follow-up provides valuable prognostic information; patients whose Gal-3 levels remain high or increase over time are at substantially greater risk for progressive ventricular dysfunction, heart failure hospitalization, and death, signaling the need for therapeutic intensification or closer monitoring (Ghorbani et al., 2018; Idzikowska et al., 2022). The gene discussed is LGALS3; the disease is heart failure.